Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fexofenadine ANDA

This article was originally published in The Tan Sheet

Executive Summary

Dr. Reddy's Labs has filed ANDA for fexofenadine 30 mg, 60 mg and 180 mg, equivalent to Aventis' Allegra, firm says March 25. Aventis subsequently filed lawsuit in New Jersey federal court alleging patent infringement on six Orange Book patents, Dr. Reddy's notes. Firm will likely switch products in future; Hyderabad, India-based Dr. Reddy's recently sealed distribution deal with Leiner to expand foothold in U.S. OTC drug market (1"The Tan Sheet" March 3, 2003, p. 3)...

You may also be interested in...

Dr. Reddy’s Stakes Claim In U.S. OTC Market With Leiner Deal

Dr. Reddy's Laboratories' foothold in the U.S. OTC drug market appears ready for expansion after the firm signed an exclusive 15-year OTC product development and marketing agreement with Leiner Health Products

Amneal Eyes Avastin And Praises $120m Biosimilar Development Savings

Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.

Zydus Cadila Testing Three-Dose COVID-19 Vaccine

Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts